FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561489460> ?p ?o ?g. }

• W2561489460 abstract "Abstract Abstract 644 Background: Omacetaxine is a first-in-class cetaxine with clinical activity against Ph+ CML and a mechanism of action independent of tyrosine kinase inhibition. Currently available tyrosine kinase inhibitors (TKIs) have not demonstrated activity in CML patients (Pts) who harbor the Bcr-Abl T315I mutation. Study Goals: To evaluate the safety and efficacy of subcutaneously (SC) administered omacetaxine in Pts with imatinib (IM)-resistant T315I+ Ph+ CML. Methods: Eligible Pts include adult CML Pts in chronic, accelerated, or blast disease phase (CP, AP, BP) with a confirmed Bcr-Abl T315I mutation and resistance to IM therapy. Induction schedule: 1.25 mg/m2 SC omacetaxine twice daily for 14 days every 28 days until hematologic response. Maintenance dosing: 1.25 mg/m2 SC omacetaxine twice daily for 7 days every 28 days. Study Results: To date, 90 Pts have been enrolled, with data available for analysis on 66 Pts (40 CP, 16 AP and 10 BP). The median age was 58 yrs (19-83) with 70% male Pts and a median disease duration of 54 mo (5-285). All Pts failed prior IM therapy, and 79% failed two or more prior TKIs. The presence of baseline T315I mutation was confirmed in all Pts. Baseline clonal evolution was evident in 10 (25%) CP, 6 (38%) AP, and 7 (70%) BP Pts. Eight CP Pts entered the study in CHR. The median follow-up for all Pts was 6.4 mo (0.2 to 29.6). Efficacy: In CP Pts, CHR was achieved in 26 Pts and maintained in 8 Pts for an overall CHR rate of 85%; the median duration of CHR was 7.7+ mo (1.7 to 23.6). Overall cytogenetic response was 27.5% with 6 (15%) Pts achieving a major cytogenetic response (MCyR, 4 complete, 2 partial). The median duration of MCyR was 6+ mo (0.8 to 16.1). Major molecular response was achieved in 15% of Pts and a reduction of baseline T315I mutated clone occurred in 56.7% of CP Pts. In AP Pts, overall hematologic response was achieved in 6 (37.5%) Pts with 5 CHR and 1 return to chronic phase (RCP). Median duration of response was 3.9+ mo (1.7 to 14.8). One AP Pt achieved a complete cytogenetic response; duration 1.9+ mo. In BP Pts, overall hematologic response was achieved in 3 (30%) Pts with 2 CHR and 1 RCP. The median overall survival for CP Pts has not been reached and 35 (88%) Pts were alive at the time of data cut- off. The median overall survival was 18.8 mo for AP and 1.8 mo for BP Pts. Median time to progression was 11.2, 3.1, and 1.2 mo for CP, AP, and BP Pts, respectively. Safety: Grade 3/4 related events occurred in 45 of 66 (68%) Pts. The most commonly reported events were thrombocytopenia (58%), anemia (36%) and neutropenia (33%). Non-hematologic toxicities were primarily grade 1/2 with the most frequently reported events of diarrhea (44%), fatigue (35%), pyrexia (32%), nausea (26%), and asthenia (21%). Grade 3/4 non-hematologic toxicities were uncommon with no events occurring in >5% of Pts and infection (3%) the most common event. Treatment delays occurred in approximately 50% of the Pts with median duration of approximately 12 days for all disease phases and cycles (CP=12, AP=10, and BP=12 days). The primary causes of delay were thrombocytopenia, neutropenia and pancytopenia. Sixteen deaths occurred during the study (5 CP, 4 AP, and 7 BP).Three deaths (1 CP, 1 AP, and 1 BP) were considered to have a possible relationship to omacetaxine: sepsis, pancytopenia, and sudden death with unknown cause, respectively. Conclusions: Omacetaxine administered by subcutaneous injection produces durable hematologic and cytogenetic responses with a safety profile consisting mainly of hematologic toxicities. Omacetaxine may provide a treatment option for this patient population who currently has no available approved drug therapies. Disclosures: Cortes-Franco: ChemGenex: Membership on an entity's Board of Directors or advisory committees, Research Funding. Khoury:ChemGenex: Membership on an entity's Board of Directors or advisory committees, Research Funding. Nicolini:ChemGenex: Research Funding. Corm:ChemGenex: Research Funding. Lipton:ChemGenex: Membership on an entity's Board of Directors or advisory committees, Research Funding. Jones:ChemGenex: Research Funding. Hochhaus:ChemGenex: Research Funding. Craig:ChemGenex: Employment. Benichou:ChemGenex: Employment. Humphriss:ChemGenex: Employment. Kantarjian:ChemGenex: Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2561489460 created "2017-01-06" @default.
• W2561489460 creator A5014346242 @default.
• W2561489460 creator A5035964802 @default.
• W2561489460 creator A5040576970 @default.
• W2561489460 creator A5052875031 @default.
• W2561489460 creator A5060146063 @default.
• W2561489460 creator A5063124046 @default.
• W2561489460 creator A5070451207 @default.
• W2561489460 creator A5072825044 @default.
• W2561489460 creator A5077014294 @default.
• W2561489460 creator A5079303243 @default.
• W2561489460 creator A5090435894 @default.
• W2561489460 date "2009-11-20" @default.
• W2561489460 modified "2023-10-01" @default.
• W2561489460 title "Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study." @default.
• W2561489460 doi "https://doi.org/10.1182/blood.v114.22.644.644" @default.
• W2561489460 hasPublicationYear "2009" @default.
• W2561489460 type Work @default.
• W2561489460 sameAs 2561489460 @default.
• W2561489460 citedByCount "21" @default.
• W2561489460 countsByYear W25614894602012 @default.
• W2561489460 countsByYear W25614894602014 @default.
• W2561489460 countsByYear W25614894602016 @default.
• W2561489460 countsByYear W25614894602017 @default.
• W2561489460 crossrefType "journal-article" @default.
• W2561489460 hasAuthorship W2561489460A5014346242 @default.
• W2561489460 hasAuthorship W2561489460A5035964802 @default.
• W2561489460 hasAuthorship W2561489460A5040576970 @default.
• W2561489460 hasAuthorship W2561489460A5052875031 @default.
• W2561489460 hasAuthorship W2561489460A5060146063 @default.
• W2561489460 hasAuthorship W2561489460A5063124046 @default.
• W2561489460 hasAuthorship W2561489460A5070451207 @default.
• W2561489460 hasAuthorship W2561489460A5072825044 @default.
• W2561489460 hasAuthorship W2561489460A5077014294 @default.
• W2561489460 hasAuthorship W2561489460A5079303243 @default.
• W2561489460 hasAuthorship W2561489460A5090435894 @default.
• W2561489460 hasConcept C126322002 @default.
• W2561489460 hasConcept C141071460 @default.
• W2561489460 hasConcept C197934379 @default.
• W2561489460 hasConcept C2777583451 @default.
• W2561489460 hasConcept C2778729363 @default.
• W2561489460 hasConcept C2779536868 @default.
• W2561489460 hasConcept C3019892230 @default.
• W2561489460 hasConcept C71924100 @default.
• W2561489460 hasConcept C90924648 @default.
• W2561489460 hasConceptScore W2561489460C126322002 @default.
• W2561489460 hasConceptScore W2561489460C141071460 @default.
• W2561489460 hasConceptScore W2561489460C197934379 @default.
• W2561489460 hasConceptScore W2561489460C2777583451 @default.
• W2561489460 hasConceptScore W2561489460C2778729363 @default.
• W2561489460 hasConceptScore W2561489460C2779536868 @default.
• W2561489460 hasConceptScore W2561489460C3019892230 @default.
• W2561489460 hasConceptScore W2561489460C71924100 @default.
• W2561489460 hasConceptScore W2561489460C90924648 @default.
• W2561489460 hasLocation W25614894601 @default.
• W2561489460 hasOpenAccess W2561489460 @default.
• W2561489460 hasPrimaryLocation W25614894601 @default.
• W2561489460 hasRelatedWork W1990020715 @default.
• W2561489460 hasRelatedWork W1999614615 @default.
• W2561489460 hasRelatedWork W2028959752 @default.
• W2561489460 hasRelatedWork W2038161969 @default.
• W2561489460 hasRelatedWork W2053131280 @default.
• W2561489460 hasRelatedWork W2054251966 @default.
• W2561489460 hasRelatedWork W2075786831 @default.
• W2561489460 hasRelatedWork W2091423586 @default.
• W2561489460 hasRelatedWork W2097799776 @default.
• W2561489460 hasRelatedWork W2097946794 @default.
• W2561489460 hasRelatedWork W2107268345 @default.
• W2561489460 hasRelatedWork W2110648386 @default.
• W2561489460 hasRelatedWork W2124196948 @default.
• W2561489460 hasRelatedWork W2143939343 @default.
• W2561489460 hasRelatedWork W2166654361 @default.
• W2561489460 hasRelatedWork W2172189430 @default.
• W2561489460 hasRelatedWork W2261840157 @default.
• W2561489460 hasRelatedWork W2561307901 @default.
• W2561489460 hasRelatedWork W2570921152 @default.
• W2561489460 hasRelatedWork W2979325951 @default.
• W2561489460 isParatext "false" @default.
• W2561489460 isRetracted "false" @default.
• W2561489460 magId "2561489460" @default.
• W2561489460 workType "article" @default.